Azurity Pharmaceuticals announced that the USFDA has approved amlodipine (Katerzia) Oral Suspension, 1 mg/mL, the first and only FDA-approved amlodipine oral suspension.
Katerzia is indicated for the treatment of hypertension in adults and paediatric patients 6 years of age and older and coronary artery disease in adults.
The drug formulation offers a ready-to-use oral suspension for children 6 years of age and older that require or prefer an oral liquid option of amlodipine.
Katerzia will be readily available through an extensive network of pharmacies and a qualified mail order service, the company said in a news release.
Azurity Pharmaceuticals is a privately-held, specialty pharmaceutical company formed by the acquisition of Silvergate Pharmaceuticals, Inc. by CutisPharma, Inc., in May 2019.